Pavlo Gilchuk1, Chad E Mire2,3, Joan B Geisbert2,3, Krystle N Agans2,3, Daniel J Deer2,3, Robert W Cross2,3, James C Slaughter4, Andrew I Flyak5, Jeremy Mani1, Michael H Pauly6, Jesus Velasco6, Kevin J Whaley6, Larry Zeitlin6, Thomas W Geisbert2,3, James E Crowe1,5,7. 1. Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, Tennessee. 2. Galveston National Laboratory, University of Texas Medical Branch, Galveston. 3. Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston. 4. Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee. 5. Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee. 6. Mapp Biopharmaceutical, San Diego, California. 7. Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee.
Abstract
Background: The 2013-2016 Ebola virus disease (EVD) epidemics in West Africa highlighted a need for effective therapeutics for treatment of the disease caused by filoviruses. Monoclonal antibodies (mAbs) are promising therapeutic candidates for prophylaxis or treatment of virus infections. Data about efficacy of human mAb monotherapy against filovirus infections in preclinical nonhuman primate models are limited. Methods: Previously, we described a large panel of human mAbs derived from the circulating memory B cells from Bundibugyo virus (BDBV) infection survivors that bind to the surface glycoprotein (GP) of the virus. We tested one of these neutralizing mAbs that recognized the glycan cap of the GP, designated mAb BDBV289, as monotherapy in rhesus macaques. Results: We found that recombinant mAb BDBV289-N could confer up to 100% protection to BDBV-infected rhesus macaques when treatment was initiated as late as 8 days after virus challenge. Protection was associated with survival and decreased viremia levels in the blood of treated animals. Conclusions: These findings define the efficacy of monotherapy of lethal BDBV infection with a glycan cap-specific mAb and identify a candidate mAb therapeutic molecule that could be included in antibody cocktails for prevention or treatment of ebolavirus infections.
Background: The 2013-2016 Ebola virus disease (EVD) epidemics in West Africa highlighted a need for effective therapeutics for treatment of the disease caused by filoviruses. Monoclonal antibodies (mAbs) are promising therapeutic candidates for prophylaxis or treatment of virus infections. Data about efficacy of human mAb monotherapy against filovirus infections in preclinical nonhuman primate models are limited. Methods: Previously, we described a large panel of human mAbs derived from the circulating memory B cells from Bundibugyo virus (BDBV) infection survivors that bind to the surface glycoprotein (GP) of the virus. We tested one of these neutralizing mAbs that recognized the glycan cap of the GP, designated mAb BDBV289, as monotherapy in rhesus macaques. Results: We found that recombinant mAb BDBV289-N could confer up to 100% protection to BDBV-infectedrhesus macaques when treatment was initiated as late as 8 days after virus challenge. Protection was associated with survival and decreased viremia levels in the blood of treated animals. Conclusions: These findings define the efficacy of monotherapy of lethal BDBV infection with a glycan cap-specific mAb and identify a candidate mAb therapeutic molecule that could be included in antibody cocktails for prevention or treatment of ebolavirus infections.
Authors: Andrew I Flyak; Philipp A Ilinykh; Charles D Murin; Tania Garron; Xiaoli Shen; Marnie L Fusco; Takao Hashiguchi; Zachary A Bornholdt; James C Slaughter; Gopal Sapparapu; Curtis Klages; Thomas G Ksiazek; Andrew B Ward; Erica Ollmann Saphire; Alexander Bukreyev; James E Crowe Journal: Cell Date: 2015-02-26 Impact factor: 41.582
Authors: Xuelian Zhao; Katie A Howell; Shihua He; Jennifer M Brannan; Anna Z Wec; Edgar Davidson; Hannah L Turner; Chi-I Chiang; Lin Lei; J Maximilian Fels; Hong Vu; Sergey Shulenin; Ashley N Turonis; Ana I Kuehne; Guodong Liu; Mi Ta; Yimeng Wang; Christopher Sundling; Yongli Xiao; Jennifer S Spence; Benjamin J Doranz; Frederick W Holtsberg; Andrew B Ward; Kartik Chandran; John M Dye; Xiangguo Qiu; Yuxing Li; M Javad Aman Journal: Cell Date: 2017-05-18 Impact factor: 41.582
Authors: Gene Garrard Olinger; James Pettitt; Do Kim; Cara Working; Ognian Bohorov; Barry Bratcher; Ernie Hiatt; Steven D Hume; Ashley K Johnson; Josh Morton; Michael Pauly; Kevin J Whaley; Calli M Lear; Julia E Biggins; Corinne Scully; Lisa Hensley; Larry Zeitlin Journal: Proc Natl Acad Sci U S A Date: 2012-10-15 Impact factor: 11.205
Authors: Xiangguo Qiu; Gary Wong; Jonathan Audet; Alexander Bello; Lisa Fernando; Judie B Alimonti; Hugues Fausther-Bovendo; Haiyan Wei; Jenna Aviles; Ernie Hiatt; Ashley Johnson; Josh Morton; Kelsi Swope; Ognian Bohorov; Natasha Bohorova; Charles Goodman; Do Kim; Michael H Pauly; Jesus Velasco; James Pettitt; Gene G Olinger; Kevin Whaley; Bianli Xu; James E Strong; Larry Zeitlin; Gary P Kobinger Journal: Nature Date: 2014-08-29 Impact factor: 49.962
Authors: Jesper Pallesen; Charles D Murin; Natalia de Val; Christopher A Cottrell; Kathryn M Hastie; Hannah L Turner; Marnie L Fusco; Andrew I Flyak; Larry Zeitlin; James E Crowe; Kristian G Andersen; Erica Ollmann Saphire; Andrew B Ward Journal: Nat Microbiol Date: 2016-08-08 Impact factor: 17.745
Authors: Lauren E Williamson; Andrew I Flyak; Nurgun Kose; Robin Bombardi; Andre Branchizio; Srikar Reddy; Edgar Davidson; Benjamin J Doranz; Marnie L Fusco; Erica O Saphire; Peter J Halfmann; Yoshihiro Kawaoka; Ashley E Piper; Pamela J Glass; James E Crowe Journal: J Virol Date: 2019-04-03 Impact factor: 5.103
Authors: Pavlo Gilchuk; Charles D Murin; Robert W Cross; Philipp A Ilinykh; Kai Huang; Natalia Kuzmina; Viktoriya Borisevich; Krystle N Agans; Joan B Geisbert; Seth J Zost; Rachel S Nargi; Rachel E Sutton; Naveenchandra Suryadevara; Robin G Bombardi; Robert H Carnahan; Alexander Bukreyev; Thomas W Geisbert; Andrew B Ward; James E Crowe Journal: Cell Date: 2021-10-28 Impact factor: 41.582
Authors: Amira D Rghei; Laura P van Lieshout; Lisa A Santry; Matthew M Guilleman; Sylvia P Thomas; Leonardo Susta; Khalil Karimi; Byram W Bridle; Sarah K Wootton Journal: Trop Med Infect Dis Date: 2020-11-09
Authors: Dominic Paquin-Proulx; Bronwyn M Gunn; Aljawharah Alrubayyi; Danielle V Clark; Matthew Creegan; Dohoon Kim; Hannah Kibuuka; Monica Millard; Salim Wakabi; Leigh Anne Eller; Nelson L Michael; Randal J Schoepp; Matthew J Hepburn; Lisa E Hensley; Merlin L Robb; Galit Alter; Michael A Eller Journal: Front Immunol Date: 2021-05-20 Impact factor: 7.561